Myriad Genetics Shares Fall Despite Partnership With Jscreen
Myriad Genetics and Jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible With Electronic Medical Record Integration
Myriad Genetics (NASDAQ:MYGN) Shareholders Are Still up 61% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $32
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $34